JAK inhibition therapy for intractable cutaneous infectious granulomatosis with unknown etiology: a case report
Year: 2026
Type: article
Study design: Case Report
Abstract: AIM: To describe the clinical response to the JAK inhibition, upadacitinib, in a patient with cutaneous infectious granulomatosis. METHODS: We reported a 36-year-old female with chronic, treatment-resistant facial and leg plaques. Histopathology supported a diagnosis of infectious granuloma, but no exact pathogen was detected after antifungal therapy. Immunohistochemical analysis indicated elevated levels of cytokines. This patient was treated with upadacitinib 15 mg daily. RESULTS: The symptoms had worsened despite prior antifungal therapy. This patient experienced rapid improvement and sustained remission following treatment with upadacitinib for pathogen-negative, immune-mediated granulomatosis. No recurrences were observed at the 8-month follow-up. CONCLUSION: This case-report highlights a potential role for JAK inhibition, upadacitinib, in managing refractory cutaneous granulomatosis with an excessive immune response despite no identifiable pathogen and pathogen clearance.
Language: English
Subfield: Epidemiology
Field: Medicine
Domain: Health Sciences
Open Access status: diamond
OpenAlex ID: W7135177567